CD73 Inhibitor Composition for Blocking Adenosine-Mediated Immune Suppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancers and other diseases mediated by CD73, such as adenosine-mediated immune suppression, lack specificity and efficacy, necessitating the development of targeted CD73 inhibitors to enhance anti-tumor responses and treat associated diseases.
Innovation Solution
Development of a CD73 inhibitor compound of formula (I) and its preparation method, which effectively inhibits the enzymatic activity of CD73, applicable for treating cancers and other diseases mediated by CD73, particularly melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, and ovarian cancer.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancers and CD73-mediated diseases are used, then broad disease coverage is achieved, but specificity and efficacy are insufficient
Solution Approach 1:
The patent introduces a small molecule inhibitor as an intermediary substance that specifically binds to the CD73 enzyme active site, blocking its catalytic activity. This intermediary approach allows selective targeting of CD73 without affecting other enzymes, thereby improving treatment specificity and efficacy for cancers and CD73-mediated diseases
Solution Approach 2:
The patent develops compounds with optimized molecular parameters including specific functional groups (sulfonamide, sulfone), ring structures (pyrimidine, pyridine), and substituent patterns that enhance binding affinity to CD73. By systematically varying these chemical parameters, the invention achieves high specificity and potency in inhibiting CD73 enzymatic activity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD73 inhibitor demonstrates strong inhibitory effects on CD73 enzymatic activity, offering a promising therapeutic strategy for cancer treatment and other CD73-mediated diseases with enhanced safety and specificity.
Implementation Method 1
CD73 plays a major role in catalyzing the conversion of extracellular monophosphate (such as 5'AMP) into their corresponding nucleosides (such as adenosine). The CD73 inhibitor demonstrates strong inhibitory effects on CD73 enzymatic activity
Data Source
AI summary
A CD73 inhibitor having the structure represented by formula (I), a preparation method therefor and an application thereof. The series of compounds can be widely applied in the preparation of drugs for treating cancers or tumors that are at least partially mediated by CD73, autoimmune diseases and disorders and metabolic diseases, in particular drugs for treating melanoma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, leukemia, brain tumor, lymphoma, ovarian cancer and Kaposi's sarcoma. A new generation of CD73 inhibitor drugs is expected to be developed.